Trials / Completed
CompletedNCT04414150
A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours
Tolerability, Safety and Pharmacokinetic Characteristics of SHR-1802 in Patients With Advanced Malignancy: a Phase I Clinical Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is the first study to test SHR-1802 in humans. The primary purpose of this study is to see if SHR-1802 is safe and tolerable for patients with locally advanced/unresectable or metastatic malignancies that are refractory to available therapy or for which no standard therapy is available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1802 | This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available. |
Timeline
- Start date
- 2020-06-17
- Primary completion
- 2022-01-13
- Completion
- 2022-03-15
- First posted
- 2020-06-04
- Last updated
- 2022-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04414150. Inclusion in this directory is not an endorsement.